Opdualag-Nivolumab And Relatlimab-Rmbw
PD-1 and CTLA-4 blockade defined melanoma immunotherapy, and LAG-3 was the third checkpoint to be validated clinically. Opdualag (nivolumab and relatlimab) delivered it. Pairing nivolumab with relatlimab, the first LAG-3 blocking antibody approved, it releases two independent brakes on exhausted T cells at once. The fixed-dose intravenous combination treats unresectable or metastatic melanoma in patients […]
Enjaymo-Sutimlimab-Jome
Cold agglutinin disease destroys red cells through classical complement activation, and patients had no approved therapy, relying on transfusion and cold avoidance. Enjaymo (sutimlimab) was the first. Sutimlimab selectively inhibits complement protein C1s, shutting down the classical pathway while leaving the alternative and lectin pathways intact. Given intravenously every two weeks after loading doses, it […]
Vabysmo-Faricimab-Svoa
Vabysmo (faricimab) targeted a second pathway alongside VEGF to extend dosing intervals, addressing the treatment burden that drives real-world under-dosing in retinal disease. By blocking both VEGF-A and angiopoietin-2, it reduces leakage and stabilizes vessels, enabling dosing up to every four months in eligible patients. The intravitreal injection was the first bispecific antibody approved for […]
Kimmtrak-Tebentafusp-Tebn
Metastatic uveal melanoma responds poorly to checkpoint inhibitors, and no therapy had ever demonstrated a survival benefit. Kimmtrak (tebentafusp) was the first to do so. It uses an engineered T-cell receptor recognizing gp100 on melanoma cells, fused to an anti-CD3 domain that physically recruits T cells to kill them. The weekly intravenous infusion treats HLA-A*02:01-positive […]
Adbry-Tralokinumab-Ldrm
Atopic dermatitis biology implicates both IL-4 and IL-13, and whether blocking IL-13 alone would suffice was an open question. Adbry (tralokinumab) tested it commercially. Tralokinumab specifically targets and neutralizes IL-13, preventing it from binding its receptors, in contrast to dupilumab’s blockade of the shared IL-4 receptor alpha subunit. The subcutaneous injection treats moderate-to-severe atopic dermatitis […]
Vyvgart-Efgartigimod Alfa-Fcab
Vyvgart (efgartigimod alfa) targeted the pathogenic IgG autoantibodies driving generalized myasthenia gravis, in a field that had relied on broad immunosuppression, plasma exchange, or IVIG. By blocking FcRn, it prevents IgG recycling so circulating antibodies, including the pathogenic ones, are cleared faster. Weekly intravenous infusions are given in cycles to adults with generalized myasthenia gravis […]
Tezspire-Tezepelumab-Ekko
Biologics transformed severe asthma but were confined to eosinophilic or allergic phenotypes, leaving patients outside those groups without options. Tezspire (tezepelumab) removed the phenotype requirement. Tezepelumab is the first biologic to block thymic stromal lymphopoietin, an epithelial alarmin upstream of multiple inflammatory cascades, which is why its label carries no phenotype or biomarker limitation. The […]
Besremi-Ropeginterferon Alfa-2b-Njft
Polycythemia vera has long been managed with phlebotomy and hydroxyurea, neither of which addresses the underlying clonal disease. Besremi (ropeginterferon alfa-2b) brought interferon into formal approval for the condition. It is a long-acting interferon injected every two weeks, with the interval extendable once hematocrit is controlled, and the first interferon approved specifically for polycythemia vera. […]
Tivdak-Tisotumab Vedotin-Tftv
Recurrent cervical cancer that progresses after chemotherapy has had few effective options, and tissue factor is unusually highly expressed in these tumors. Tivdak (tisotumab vedotin) exploited that. Tisotumab vedotin was the first tissue factor-directed therapy approved, delivering the microtubule-disrupting agent MMAE into tumor cells after binding and internalization. The intravenous conjugate treats adults with recurrent […]
Skytrofa-Lonapegsomatropin-Tcgd
Growth hormone deficiency has meant daily injections for children, a burden that erodes adherence over years of treatment. Skytrofa (lonapegsomatropin) was among the first long-acting alternatives approved in the U.S. It is a prodrug in which somatropin is bound to a carrier and released gradually through a cleavable linker, producing sustained exposure from a single […]
